% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Endepols:863617,
      author       = {Endepols, Heike and Morgenroth, Agnieszka and Zlatopolskiy,
                      Boris D. and Krapf, Philipp and Zischler, Johannes and
                      Richarz, Raphael and Muñoz Vásquez, Sergio and Neumaier,
                      Bernd and Mottaghy, Felix M.},
      title        = {{P}eripheral ganglia in healthy rats as target structures
                      for the evaluation of {PSMA} imaging agents},
      journal      = {BMC cancer},
      volume       = {19},
      number       = {1},
      issn         = {1471-2407},
      address      = {Heidelberg},
      publisher    = {Springer},
      reportid     = {FZJ-2019-03629},
      pages        = {633},
      year         = {2019},
      abstract     = {BACKGROUND:The recent implementation of PET with prostate
                      specific membrane antigen (PSMA)-specific radiotracers into
                      the clinical practice has resulted in the significant
                      improvement of accuracy in the detection of prostate
                      carcinoma (PCa). PSMA-expression in ganglia has been
                      regarded as an important pitfall in prostate carcinoma-PET
                      diagnostics but has not found any practical use for
                      diagnosis or therapy.METHODS:We explored this phenomenon and
                      demonstrated the applicability of peripheral ganglia in
                      healthy rats as surrogates for small PSMA positive lesions
                      for the preclinical evaluation of diagnostic PCa PET probes.
                      Healthy rats were measured with PET/CT using the tracers
                      [18F]DCFPyL, [Al18F]PSMA-11 and [68Ga]PSMA-11. Sections of
                      ganglia were stained with an anti-PSMA antibody. [18F]DCFPyL
                      uptake in ganglia was compared to that in LNCaP tumor
                      xenografts in mice.RESULTS:Whereas [18F]DCFPyL and
                      [68Ga]PSMA-11 were stable in vivo and accumulated in
                      peripheral ganglia, [Al18F]PSMA-11 suffered from fast in
                      vivo deflourination resulting in high bone uptake.
                      Ganglionic PSMA expression was confirmed by
                      immunohistochemistry. [18F]DCFPyL uptake and signal-to-noise
                      ratio in the superior cervical ganglion was not
                      significantly different from LNCaP
                      xenografts.CONCLUSIONS:Our results demonstrated the
                      non-inferiority of the novel model compared to
                      conventionally used tumor xenografts in immune compromised
                      rodents with regard to reproducibility and stability of the
                      PSMA signal. Furthermore, the model involves less expense
                      and efforts while it is permanently available and avoids
                      tumor-growth associated animal morbidity and distress. To
                      the best of our knowledge, this is the first tumor-free
                      model suitable for the in vivo evaluation of tumor imaging
                      agents.},
      cin          = {INM-5},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-5-20090406},
      pnm          = {573 - Neuroimaging (POF3-573)},
      pid          = {G:(DE-HGF)POF3-573},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31242896},
      UT           = {WOS:000473007000002},
      doi          = {10.1186/s12885-019-5841-8},
      url          = {https://juser.fz-juelich.de/record/863617},
}